This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           August 27, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Pemetrexed plus cisplatin active in advanced, recurrent cervical carcinoma
The combination of pemetrexed and cisplatin appeared safe and effective in women with advanced, persistent or recurrent carcinoma of the cervix, according to results of a phase 2 trial published in the Journal of Clinical Oncology. “This combination should be further developed in the treatment of cervical cancer,” David Scott Miller, MD, professor of obstetrics and gynecology at UT Southwestern Medical Center, and colleagues wrote. “Given that it may be less toxic than and as active as cisplatin plus paclitaxel, and that it can be combined with bevacizumab (Avastin, Genentech), comparison of cisplatin–pemetrexed plus bevacizumab with cisplatin–paclitaxel plus bevacizumab would be appropriate.”
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Report shows HPV vaccine trials can be shortened significantly
Infection Control Today
A new report, Primary End-points for Prophylactic HPV Vaccine Trials, from a working group convened by the International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization, and the United States National Cancer Institute (NCI) shows how the evaluation and licensing of prophylactic human papillomavirus (HPV) vaccines could be significantly accelerated. Experts with wide-ranging expertise in HPV vaccines reviewed the scientific evidence to determine under what circumstances vaccine efficacy can be established at an earlier stage of the infection, rather than the clinical onset of disease in the cervix.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

HTI-1968 shuts down HPV that causes most cervical cancer
The Pharma Letter (Subscription required)
Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being developed by privately-held US firm Hera Therapeutics combats three types of human papillomavirus, including the two that cause 70 percent of all cervical cancer. When tested in several cultured human cell models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according to Louise Chow and Thomas Broker, who presented the findings at the Seattle conference.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.


DHEA therapy offers relief from vaginal symptoms in cancer survivors
A randomized multicenter trial examining the efficacy of adding dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women, and that when DHEA is added, survivors report significant improvements in sexual desire, arousal, pain, and overall sexual function.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Work for the best
We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201. MORE
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.


Medicaid: Do differing state reimbursement policies affect cancer screening?
Medical News Today
Although Medicaid programs across the U.S. provide access to breast, cervical and colorectal cancer screening, there is no guarantee that these services will be fully utilized. Evidence published in Cancer suggests that Medicaid users were less likely to receive cancer screening than individuals with private health insurance, and they were more likely to present themselves with advanced stages of cancer than individuals with private health insurance or Medicare provision.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Bisphosphonate treatment did not reduce risk for postmenopausal breast cancer
HemOnc Today
Treatment with bisphosphonates for osteoporosis provided no protective effect against the risk for invasive postmenopausal breast cancer, according to an analysis of results from two randomized, double blind, placebo-controlled trials published in JAMA. These results contradict findings from observational studies that suggest bisphosphonates may suppress the proliferation of estrogen-sensitive breast cancer cells.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Aug. 20, 2014
Aug. 13, 2014
Aug. 6, 2014
July 23, 2014

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063